Novel agent #2714 potently inhibits lung cancer growth by suppressing cell proliferation and by inducing apoptosis in vitro and in vivo

Lu,Wenjie; Sun,Qianqian; Chen,Bo; Li,Yan; Xu,Youzhi; Wang,Siying

doi:10.3892/mmr.2019.10114

Novel agent #2714 potently inhibits lung cancer growth by suppressing cell proliferation and by inducing apoptosis in vitro and in vivo

Authors:
- Wenjie Lu
- Qianqian Sun
- Bo Chen
- Yan Li
- Youzhi Xu
- Siying Wang
View Affiliations

Affiliations: School of Basic Medicine, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Pharmacodynamics Pharmacokinetics Early Safety Evaluation Model Animals, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: April 2, 2019 https://doi.org/10.3892/mmr.2019.10114
Pages: 4788-4796
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The use of small molecule compounds to inhibit cell proliferation is one of the most promising approaches in cancer therapy. In the present study, a cell viability assay, flow cytometry analysis, western blotting and mouse xenograft models were used to investigate the anticancer activities of #2714 and its underlying mechanisms in lung cancer. The present in vitro results suggested that #2714 significantly inhibited the viability of the human non‑small cell lung cancer line SPC‑A1 in a concentration‑ and time‑dependent manner, with a half‑maximal inhibitory concentration value of 5.54 µM after 48 h of treatment. Additionally, #2714 inhibited SPC‑A1 cell proliferation via the Wnt/β‑catenin pathway and by impairing mitochondrial membrane potential. The protein expression levels of Wnt 3a, Wnt 5a/b, phosphorylated (p)‑β‑catenin, p‑glycogen synthase kinase 3β, and p‑mitogen‑activated protein kinase 14 were downregulated following treatment with #2714. Furthermore, using a mouse xenograft model, #2714 was identified to significantly inhibit tumor growth and to decrease cancer cell proliferation in vivo. #2714 may represent a novel effective anticancer compound targeting lung cancer cells. Additionally, #2714 was able to induce apoptosis and decrease cell proliferation in SPC‑A1 cells via the Wnt/β‑catenin pathway.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T and Dive C: Progress and prospects of early detection in lung cancer. Open Biol. 7:1700702017. View Article : Google Scholar : PubMed/NCBI
3	Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, et al: Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer. 14:182014. View Article : Google Scholar : PubMed/NCBI
4	Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
5	Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry D: Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
6	Brückl W, Tufman A and Huber RM: Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: First-line treatment with afatinib and other EGFR TKIs. Expert Rev Anticancer Ther. 17:143–155. 2017. View Article : Google Scholar : PubMed/NCBI
7	Lu WJ, Peng W, Sun QQ, Li YH, Chen B, Yu LT, Xu YZ, Wang SY and Zhao YL: #2714, a novel active inhibitor with potent arrested G2/M phase and antitumor efficacy in preclinical models. Cell Death Discov. 4:242018. View Article : Google Scholar : PubMed/NCBI
8	Xu YZ, Zheng RL, Zhou Y, Peng F, Lin HJ, Bu Q, Mao YQ, Yu LT, Yang L and Yang SY: Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway in vitro and inhibits tumor growth in vivo. Cancer Lett. 313:44–53. 2011. View Article : Google Scholar : PubMed/NCBI
9	Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF and Testa JR: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA. 98:247–252. 2001. View Article : Google Scholar : PubMed/NCBI
10	Downward J: Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells. Oncogene. 23:8376–8383. 2004. View Article : Google Scholar : PubMed/NCBI
11	Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
12	Printz C: Targeted therapy in lung cancer: Survival, quality of life improved for some patients. Cancer. 120:2625–2626. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, et al: Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 30:3337–3344. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hartmann JT, Haap M, Kopp HG and Lipp HP: Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab. 10:470–481. 2009. View Article : Google Scholar : PubMed/NCBI
15	Anastas JN and Moon RT: WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 13:11–26. 2012. View Article : Google Scholar
16	Brown K, Yang P, Salvador D, Kulikauskas R, Ruoholabaker H, Robitaille AM, Chien AJ, Moon RT and Sherwood V: WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner. Oncogene. 36:3119–3136. 2017. View Article : Google Scholar : PubMed/NCBI
17	Regmi SC, Park SY, Kim SJ, Banskota S, Shah S, Kim DH and Kim JA: The anti-tumor activity of Succinyl Macrolactin A is mediated through the β-catenin destruction complex via the suppression of tankyrase and PI3K/Akt. PLoS One. 10:e01417532015. View Article : Google Scholar : PubMed/NCBI
18	Zhan T, Rindtorff N and Boutros M: Wnt signaling in cancer. Oncogene. 36:1461–1473. 2018. View Article : Google Scholar
19	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
20	Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A and Aaronson SA: Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene. 28:2163–2172. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kreuzaler P and Watson CJ: Killing a cancer: What are the alternatives? Nat Rev Cancer. 12:411–424. 2012. View Article : Google Scholar : PubMed/NCBI
22	Shalini S, Dorstyn L, Dawar S and Kumar S: Old, new and emerging functions of caspases. Cell Death Differ. 22:526–539. 2015. View Article : Google Scholar : PubMed/NCBI
23	Pradelli LA, Bénéteau M and Ricci JE: Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol Life Sci. 67:1589–1597. 2010. View Article : Google Scholar : PubMed/NCBI
24	Denisenko TV, Budkevich IN and Zhivotovsky B: Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 9:1172018. View Article : Google Scholar : PubMed/NCBI
25	Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E and Boise LH: Caspase-9, caspase- 3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 14:322013. View Article : Google Scholar : PubMed/NCBI
26	Azmi AS, Wang Z, Philip PA, Mohammad RM and Sarkar FH: Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs. 16:59–70. 2011. View Article : Google Scholar : PubMed/NCBI
27	Wells A, Grahovac J, Wheeler S, Ma B and Lauffenburger D: Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 34:283–289. 2013. View Article : Google Scholar : PubMed/NCBI
28	Xu YZ, Li YH, Lu WJ, Lu K, Wang CT, Li Y, Lin HJ, Kan LX, Yang SY, Wang SY and Zhao YL: YL4073 is a potent autophagy-stimulating antitumor agent in an in vivo model of Lewis lung carcinoma. Oncol Rep. 35:2081–2088. 2016. View Article : Google Scholar : PubMed/NCBI
29	Xu Y, Lu W, Yang P, Peng W, Wang C, Li M, Li Y, Li G, Meng N, Lin H, et al: A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities. BMC Cancer. 15:5252015. View Article : Google Scholar : PubMed/NCBI
30	Zheng RL, Zeng XX, He HY, He J, Yang SY, Yu YT and Yang L: Facile synthesis of 6-Aryl-3-cyanopyridine-2-(1H)-thiones from Aryl Ketones. J Synthetic Commun. 42:1521–1531. 2012. View Article : Google Scholar
31	Kilkenny C, Browne W, Cuthill IC, Emerson M and Altman DG; NC3Rs Reporting Guidelines Working Group, : Animal research: Reporting in vivo experiments: The ARRIVE guidelines. J Physiol. 160:1577–1579. 2010.
32	Mitrofanova A, Aytes A, Zou M, Shen MM, Abate-Shen C and Califano A: Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models. Cell Rep. 12:2060–2071. 2015. View Article : Google Scholar : PubMed/NCBI
33	Awazu Y, Nakamura K, Mizutani A, Kakoi Y, Iwata H, Yamasaki S, Miyamoto N, Imamura S, Miki H and Hori A: A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities. Mol Cancer Ther. 12:913–924. 2013. View Article : Google Scholar : PubMed/NCBI
34	Niehrs C: The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 13:767–779. 2012. View Article : Google Scholar : PubMed/NCBI
35	Villanueva MT: Targeted therapies: Priming apoptosis. Nat Rev Clin Oncol. 10:672013. View Article : Google Scholar : PubMed/NCBI
36	Sarosiek KA, Fraser C, Muthalagu N, BholaP D, Chang WT, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, et al: Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell. 31:142–156. 2017. View Article : Google Scholar : PubMed/NCBI
37	Fulda S: The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets. 9:729–737. 2014. View Article : Google Scholar
38	Davidson SM, Lopaschuk GD, Spedding M and Beart PM: Mitochondrial pharmacology: Energy, injury and beyond. Br J Pharmacol. 171:1795–1797. 2014. View Article : Google Scholar : PubMed/NCBI